Papagelopoulos PJ, Mavrogenis AF, Mitsiokapa EA, et al. Current trends in the management of extra-abdominal desmoid tumours. World J Surg Oncol 2006;4:21.
Molloy AP, Hutchinson B, O’Toole GC. Extra-abdom- inal desmoid tumours: a review of the literature. Sarcoma 2012;2012:578052.
Shido Y, Nishida Y, Nakashima H, et al. Surgical treatment for local control of extremity and trunk desmoid tumors. Arch Orthop Trauma Surg 2009;129(7):929-33.
Escobar C, Munker R, Thomas JO, et al. Update on desmoid tumors. Ann Oncol 2012;23(3):562-9.
Melis M, Zager JS, Sondak VK. Multimodality manage- ment of desmoid tumors: how important is a negative surgical margin? J Surg Oncol 2008;98(8):594-602.
Walczak BE, Rose PS. Desmoid: the role of local therapy in an era of systemic options. Curr Treat Options Oncol 2013;14(3):465-73
von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2014. J Natl Compr Canc Netw 2014;12(4):473-83.
Devata S, Chugh R. Desmoid tumors: a comprehensive review of the evolving biology, unpredictable behavior, and myriad of management options. Hematol Oncol Clin North Am 2013;27(5):989-1005.
Goldblum J, Fletcher J. Desmoid-type fibromatoses. World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. 2002:83-4.
Hamada S, Urakawa H, Kozawa E, et al. Nuclear expression of β-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors. Tumour Biol 2014;35(5):4561-6.
Nishida Y, Tsukushi S, Shido Y, et al. Successful treat- ment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study. J Clin Oncol 2010;28(6):e107-9.
Tanaka K, Yoshikawa R, Yanagi H, et al. Regression of sporadic intra-abdominal desmoid tumour following administration of non-steroidal anti-inflammatory drug. World J Surg Oncol 2008;6:17.
Poon R, Smits R, Li C, et al. Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene 2001;20(4):451-60.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guide- lines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-16.
Mehta S, Belcher HJ. A single-centre cost comparison an- alysis of collagenase injection versus surgical fasciecto- my for Dupuytren’s contracture of the hand. J Plast Re- constr Aesthet Surg 2014;67(3):368-72.
Naam NH. Functional outcome of collagenase injections compared with fasciectomy in treatment of Dupuytren’s contracture. Hand (N Y) 2013;8(4):410-6.
Church JM. Desmoid tumours in patients with familial adenomatous polyposis. Semin Colon Rectal Surgery 1995;6:29-32.
Stoeckle E, Coindre JM, Longy M, et al. A critical analy- sis of treatment strategies in desmoid tumours: a review of a series of 106 cases. Eur J Surg Oncol 2009;35(2):129- 34.
Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009;16(9):2587-93.
Chew C, Reid R, O’Dwyer PJ. Evaluation of the long term outcome of patients with extremity desmoids. Eur J Surg Oncol 2004;30(4):428-32.
Jenkins NH, Freedman LS, McKibbin B. Spontaneous regression of a desmoid tumour. J Bone Joint Surg Br 1986;68(5):780-1.
Nakayama T, Tsuboyama T, Toguchida J, et al. Natural course of desmoid-type fibromatosis. J Orthop Sci 2008; 13(1):51-5.
